{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:32:15Z","timestamp":1789824735884,"version":"4.0.1"},"reference-count":87,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,2,5]],"date-time":"2013-02-05T00:00:00Z","timestamp":1360022400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00467-012-2381-8","type":"journal-article","created":{"date-parts":[[2013,2,4]],"date-time":"2013-02-04T13:17:03Z","timestamp":1359983823000},"page":"617-625","source":"Crossref","is-referenced-by-count":24,"title":["Phosphate binders, vitamin D and calcimimetics in the management of chronic kidney disease\u2013mineral bone disorders (CKD-MBD) in children"],"prefix":"10.1007","volume":"28","author":[{"given":"Katherine","family":"Wesseling-Perry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro B.","family":"Salusky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,2,5]]},"reference":[{"key":"2381_CR1","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.ki.5000414","volume":"69","author":"S Moe","year":"2006","unstructured":"Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 69:1945\u20131953","journal-title":"Kidney Int"},{"key":"2381_CR2","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0022-3476(86)81064-2","volume":"108","author":"IB Salusky","year":"1986","unstructured":"Salusky IB, Coburn JW, Foley J, Nelson P, Fine RN (1986) Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 108:767\u2013770","journal-title":"J Pediatr"},{"key":"2381_CR3","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1523-1755.1998.00045.x","volume":"54","author":"IB Salusky","year":"1998","unstructured":"Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, Goodman WG (1998) Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54:907\u2013914","journal-title":"Kidney Int"},{"key":"2381_CR4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJM200005183422003","volume":"342","author":"WG Goodman","year":"2000","unstructured":"Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342:1478\u20131483","journal-title":"N Engl J Med"},{"key":"2381_CR5","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.2011.490","volume":"81","author":"DM Spiegel","year":"2012","unstructured":"Spiegel DM, Brady K (2012) Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets. Kidney Int 81:1116\u20131122","journal-title":"Kidney Int"},{"key":"2381_CR6","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/S0272-6386(05)01244-8","volume":"46","author":"F National Kidney","year":"2005","unstructured":"National Kidney F (2005) K\/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 46:S1\u2013S121","journal-title":"Am J Kidney Dis"},{"key":"2381_CR7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0272-6386(99)70221-0","volume":"33","author":"AJ Bleyer","year":"1999","unstructured":"Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E (1999) A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 33:694\u2013701","journal-title":"Am J Kidney Dis"},{"key":"2381_CR8","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1093\/ndt\/14.12.2907","volume":"14","author":"GM Chertow","year":"1999","unstructured":"Chertow GM, Burke SK, Dillon MA, Slatopolsky E (1999) Long-term effects of sevelamer hydrochloride on the calcium \u00d7 phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 14:2907\u20132914","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR9","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1046\/j.1523-1755.2002.00434.x","volume":"62","author":"GM Chertow","year":"2002","unstructured":"Chertow GM, Burke SK, Raggi P (2002) Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62:245\u2013252","journal-title":"Kidney Int"},{"key":"2381_CR10","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2215\/CJN.03820411","volume":"7","author":"B Iorio Di","year":"2012","unstructured":"Di Iorio B, Bellasi A, Russo D (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 7:487\u2013493","journal-title":"Clin J Am Soc Nephrol"},{"key":"2381_CR11","first-page":"18","volume":"51","author":"GM Chertow","year":"1999","unstructured":"Chertow GM, Dillon M, Burke SK, Steg M, Bleyer AJ, Garrett BN, Domoto DT, Wilkes BM, Wombolt DG, Slatopolsky E (1999) A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 51:18\u201326","journal-title":"Clin Nephrol"},{"key":"2381_CR12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/ki.2010.307","volume":"78","author":"D Russo","year":"2010","unstructured":"Russo D, Battaglia Y, Buonanno E (2010) Phosphorus and coronary calcification in predialysis patients. Kidney Int 78:818","journal-title":"Kidney Int"},{"key":"2381_CR13","doi-asserted-by":"crossref","first-page":"c61","DOI":"10.1159\/000088932","volume":"102","author":"AJ Hutchison","year":"2006","unstructured":"Hutchison AJ, Maes B, Vanwalleghem J, Asmus G, Mohamed E, Schmieder R, Backs W, Jamar R, Vosskuhler A (2006) Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 102:c61\u2013c71","journal-title":"Nephron Clin Pract"},{"key":"2381_CR14","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2215\/CJN.02830608","volume":"4","author":"SM Sprague","year":"2009","unstructured":"Sprague SM, Abboud H, Qiu P, Dauphin M, Zhang P, Finn W (2009) Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 4:178\u2013185","journal-title":"Clin J Am Soc Nephrol"},{"key":"2381_CR15","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1111\/j.1523-1755.2005.00753.x","volume":"68","author":"E Slatopolsky","year":"2005","unstructured":"Slatopolsky E, Liapis H, Finch J (2005) Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 68:2809\u20132813","journal-title":"Kidney Int"},{"key":"2381_CR16","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1093\/ndt\/gfl146","volume":"21","author":"GB Spasovski","year":"2006","unstructured":"Spasovski GB, Sikole A, Gelev S, Masin-Spasovska J, Freemont T, Webster I, Gill M, Jones C, De Broe ME, D\u2019Haese PC (2006) Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1\u00a0year of treatment with lanthanum carbonate and after 2\u00a0years of follow-up. Nephrol Dial Transplant 21:2217\u20132224","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR17","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S0140-6736(86)90987-6","volume":"1","author":"R O\u2019Donovan","year":"1986","unstructured":"O\u2019Donovan R, Baldwin D, Hammer M, Moniz C, Parsons V (1986) Substitution of aluminium salts by magnesium salts in control of dialysis hyperphosphataemia. Lancet 1:880\u2013882","journal-title":"Lancet"},{"key":"2381_CR18","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/ndt\/14.4.863","volume":"14","author":"O Hergesell","year":"1999","unstructured":"Hergesell O, Ritz E (1999) Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 14:863\u2013867","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR19","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/ndt\/gfq419","volume":"26","author":"T Isakova","year":"2011","unstructured":"Isakova T, Gutierrez OM, Smith K, Epstein M, Keating LK, J\u00fcppner H, Wolf M (2011) Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 26:584\u2013591","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","volume":"5","author":"RB Oliveira","year":"2010","unstructured":"Oliveira RB, Cancela AL, Graciolli FG, dos Reis LM, Draibe SA, Cuppari L, Carvalho AB, Jorgetti V, Canziani ME, Moyses RM (2010) Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 5:286\u2013291","journal-title":"Clin J Am Soc Nephrol"},{"key":"2381_CR21","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1093\/ndt\/gfr144","volume":"266","author":"E Gonzalez-Parra","year":"2011","unstructured":"Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, Martinez-Calero A, Navas V, Rodriguez M, Ortiz A (2011) Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 266:2567\u20132571","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1681\/ASN.2012030223","volume":"23","author":"GA Block","year":"2012","unstructured":"Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM (2012) Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23:1407\u20131415","journal-title":"J Am Soc Nephrol"},{"key":"2381_CR23","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1258\/acb.2012.011274","volume":"49","author":"DC Fischer","year":"2012","unstructured":"Fischer DC, Mischek A, Wolf S, Rahn A, Salweski B, Kundt G, Haffner D (2012) Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. Ann Clin Biochem 49:546\u2013553","journal-title":"Ann Clin Biochem"},{"key":"2381_CR24","doi-asserted-by":"crossref","first-page":"216","DOI":"10.2215\/CJN.04760511","volume":"7","author":"R Shroff","year":"2012","unstructured":"Shroff R, Wan M, Gullett A, Ledermann S, Shute R, Knott C, Wells D, Aitkenhead H, Manickavasagar B, van\u2019t Hoff W, Rees L (2012) Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 7:216\u2013223","journal-title":"Clin J Am Soc Nephrol"},{"key":"2381_CR25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.ki.5000394","volume":"70","author":"CS Ritter","year":"2006","unstructured":"Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ (2006) 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 70:654\u2013659","journal-title":"Kidney Int"},{"key":"2381_CR26","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1359\/jbmr.090728","volume":"25","author":"M Priemel","year":"2010","unstructured":"Priemel M, von Domarus C, Klatte TO, Kessler S, Schlie J, Meier S, Proksch N, Pastor F, Netter C, Streichert T, Puschel K, Amling M (2010) Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 25:305\u2013312","journal-title":"J Bone Miner Res"},{"key":"2381_CR27","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/S0022-3476(82)80602-1","volume":"100","author":"CB Langman","year":"1982","unstructured":"Langman CB, Mazur AT, Baron R, Norman ME (1982) 25-hydroxyvitamin D3 (calcifediol) therapy of juvenile renal osteodystrophy: beneficial effect on linear growth velocity. J Pediatr 100:815\u2013820","journal-title":"J Pediatr"},{"key":"2381_CR28","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1681\/ASN.2006060573","volume":"18","author":"GM London","year":"2007","unstructured":"London GM, Guerin AP, Verbeke FH, Pannier B, Boutouyrie P, Marchais SJ, Metivier F (2007) Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 18:613\u2013620","journal-title":"J Am Soc Nephrol"},{"key":"2381_CR29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","volume":"72","author":"M Wolf","year":"2007","unstructured":"Wolf M, Shah A, Gutierrez O, Ankers E, Monroy M, Tamez H, Steele D, Chang Y, Camargo CA Jr, Tonelli M, Thadhani R (2007) Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int 72:1004\u20131013","journal-title":"Kidney Int"},{"key":"2381_CR30","doi-asserted-by":"crossref","first-page":"c132","DOI":"10.1159\/000098645","volume":"105","author":"G Saab","year":"2007","unstructured":"Saab G, Young DO, Gincherman Y, Giles K, Norwood K, Coyne DW (2007) Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients. Nephron Clin Pract 105:c132\u2013c138","journal-title":"Nephron Clin Pract"},{"key":"2381_CR31","doi-asserted-by":"crossref","first-page":"624","DOI":"10.2215\/CJN.10030911","volume":"7","author":"SA Burnett-Bowie","year":"2012","unstructured":"Burnett-Bowie SA, Leder BZ, Henao MP, Baldwin CM, Hayden DL, Finkelstein JS (2012) Randomized trial assessing the effects of ergocalciferol administration on circulating FGF23. Clin J Am Soc Nephrol 7:624\u2013631","journal-title":"Clin J Am Soc Nephrol"},{"key":"2381_CR32","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1681\/ASN.2006080936","volume":"18","author":"D Fliser","year":"2007","unstructured":"Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P (2007) Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 18:2600\u20132608","journal-title":"J Am Soc Nephrol"},{"key":"2381_CR33","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","volume":"121","author":"C Faul","year":"2011","unstructured":"Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutierrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro OM, Kusek JW, Keane MG, Wolf M (2011) FGF23 induces left ventricular hypertrophy. J Clin Invest 121:4393\u20134408","journal-title":"J Clin Invest"},{"key":"2381_CR34","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","volume":"359","author":"OM Gutierrez","year":"2008","unstructured":"Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, J\u00fcppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584\u2013592","journal-title":"N Engl J Med"},{"key":"2381_CR35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1681\/ASN.2010080894","volume":"22","author":"M Wolf","year":"2011","unstructured":"Wolf M, Molnar MZ, Amaral AP, Czira ME, Rudas A, Ujszaszi A, Kiss I, Rosivall L, Kosa J, Lakatos P, Kovesdy CP, Mucsi I (2011) Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 22:956\u2013966","journal-title":"J Am Soc Nephrol"},{"key":"2381_CR36","unstructured":"Institute of Medicine of The National Aacademies (2011) Dietary reference intakes for calcium and vitamin D. Available at: http:\/\/www.iom.edu\/Reports\/2010\/Dietary-Reference-Intakes-for-Calcium-and-Vitamin-D.aspx"},{"key":"2381_CR37","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00467-005-2082-7","volume":"21","author":"G Klaus","year":"2006","unstructured":"Klaus G, Watson A, Edefonti A, Fischbach M, Ronnholm K, Schaefer F, Simkova E, Stefanidis CJ, Strazdins V, Vande Walle J, Schroder C, Zurowska A, Ekim M (2006) Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines. Pediatr Nephrol 21:151\u2013159","journal-title":"Pediatr Nephrol"},{"key":"2381_CR38","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1542\/peds.2008-0634","volume":"123","author":"FN Ali","year":"2009","unstructured":"Ali FN, Arguelles LM, Langman CB, Price HE (2009) Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic. Pediatrics 123:791\u2013796","journal-title":"Pediatrics"},{"key":"2381_CR39","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1053\/j.ajkd.2005.02.029","volume":"45","author":"RE LaClair","year":"2005","unstructured":"LaClair RE, Hellman RN, Karp SL, Kraus M, Ofner S, Li Q, Graves KL, Moe SM (2005) Prevalence of calcidiol deficiency in CKD: a cross-sectional study across latitudes in the United States. Am J Kidney Dis 45:1026\u20131033","journal-title":"Am J Kidney Dis"},{"key":"2381_CR40","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1136\/adc.2007.134866","volume":"93","author":"V Belostotsky","year":"2008","unstructured":"Belostotsky V, Mughal MZ, Berry JL, Webb NJ (2008) Vitamin D deficiency in children with renal disease. Arch Dis Child 93:959\u2013962","journal-title":"Arch Dis Child"},{"key":"2381_CR41","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1007\/s00467-010-1639-2","volume":"25","author":"P Hari","year":"2010","unstructured":"Hari P, Gupta N, Hari S, Gulati A, Mahajan P, Bagga A (2010) Vitamin D insufficiency and effect of cholecalciferol in children with chronic kidney disease. Pediatr Nephrol 25:2483\u20132488","journal-title":"Pediatr Nephrol"},{"key":"2381_CR42","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1007\/s00467-008-0842-x","volume":"23","author":"S Menon","year":"2008","unstructured":"Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK (2008) Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 23:1831\u20131836","journal-title":"Pediatr Nephrol"},{"key":"2381_CR43","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jsbmb.2006.12.054","volume":"103","author":"TK Barthel","year":"2007","unstructured":"Barthel TK, Mathern DR, Whitfield GK, Haussler CA, Hopper HA, Hsieh JC, Slater SA, Hsieh G, Kaczmarska M, Jurutka PW, Kolek OI, Ghishan FK, Haussler MR (2007) 1,25-Dihydroxyvitamin D3\/VDR-mediated induction of FGF23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol 103:381\u2013388","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2381_CR44","first-page":"4003","volume":"117","author":"IZ Ben-Dov","year":"2007","unstructured":"Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro O, Mohammadi M, Sirkis R, Naveh-Many T, Silver J (2007) The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003\u20134008","journal-title":"J Clin Invest"},{"key":"2381_CR45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1677\/JOE-07-0267","volume":"195","author":"T Krajisnik","year":"2007","unstructured":"Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE (2007) Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125\u2013131","journal-title":"J Endocrinol"},{"key":"2381_CR46","first-page":"185","volume":"26","author":"LR Baker","year":"1986","unstructured":"Baker LR, Muir JW, Sharman VL, Abrams SM, Greenwood RN, Cattell WR, Goodwin FJ, Marsh FP, Adami S, Hately W (1986) Controlled trial of calcitriol in hemodialysis patients. Clin Nephrol 26:185\u2013191","journal-title":"Clin Nephrol"},{"key":"2381_CR47","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/adc.52.6.473","volume":"52","author":"JA Kanis","year":"1977","unstructured":"Kanis JA, Henderson RG, Heynen G, Ledingham JG, Russell RG, Smith R, Walton RJ (1977) Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol. Arch Dis Child 52:473\u2013481","journal-title":"Arch Dis Child"},{"key":"2381_CR48","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1056\/NEJMoa022536","volume":"349","author":"M Teng","year":"2003","unstructured":"Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446\u2013456","journal-title":"N Engl J Med"},{"key":"2381_CR49","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1681\/ASN.2004070573","volume":"16","author":"M Teng","year":"2005","unstructured":"Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernan MA, Camargo CA Jr, Thadhani R (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115\u20131125","journal-title":"J Am Soc Nephrol"},{"key":"2381_CR50","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1038\/sj.ki.5001868","volume":"70","author":"F Tentori","year":"2006","unstructured":"Tentori F, Hunt WC, Stidley CA, Rohrscheib MR, Bedrick EJ, Meyer KB, Johnson HK, Zager PG (2006) Mortality risk among hemodialysis patients receiving different vitamin D analogs. Kidney Int 70:1858\u20131865","journal-title":"Kidney Int"},{"key":"2381_CR51","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1073\/pnas.0611202104","volume":"104","author":"N Bodyak","year":"2007","unstructured":"Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 104:16810\u201316815","journal-title":"Proc Natl Acad Sci USA"},{"key":"2381_CR52","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1542-4758.2007.00211.x","volume":"11","author":"NP Singh","year":"2007","unstructured":"Singh NP, Sahni V, Garg D, Nair M (2007) Effect of pharmacological suppression of secondary hyperparathyroidism on cardiovascular hemodynamics in predialysis CKD patients: a preliminary observation. Hemodial Int 11:417\u2013423","journal-title":"Hemodial Int"},{"key":"2381_CR53","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1046\/j.1523-1755.1998.00951.x","volume":"53","author":"U Schwarz","year":"1998","unstructured":"Schwarz U, Amann K, Orth SR, Simonaviciene A, Wessels S, Ritz E (1998) Effect of 1,25 (OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats. Kidney Int 53:1696\u20131705","journal-title":"Kidney Int"},{"key":"2381_CR54","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1111\/j.1523-1755.2005.00755.x","volume":"68","author":"R Agarwal","year":"2005","unstructured":"Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823\u20132828","journal-title":"Kidney Int"},{"key":"2381_CR55","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/ki.1990.293","volume":"38","author":"DS Milliner","year":"1990","unstructured":"Milliner DS, Zinsmeister AR, Lieberman E, Landing B (1990) Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38:931\u2013936","journal-title":"Kidney Int"},{"key":"2381_CR56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","volume":"47","author":"D Coyne","year":"2006","unstructured":"Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM (2006) Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 47:263\u2013276","journal-title":"Am J Kidney Dis"},{"key":"2381_CR57","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1053\/j.ajkd.2007.03.008","volume":"49","author":"LA Greenbaum","year":"2007","unstructured":"Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB (2007) Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis. Am J Kidney Dis 49:814\u2013823","journal-title":"Am J Kidney Dis"},{"key":"2381_CR58","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3181\/00379727-178-42028","volume":"178","author":"G Sjoden","year":"1985","unstructured":"Sjoden G, Smith C, Lindgren U, DeLuca HF (1985) 1 alpha-Hydroxyvitamin D2 is less toxic than 1 alpha-hydroxyvitamin D3 in the rat. Proc Soc Exp Biol Med 178:432\u2013436","journal-title":"Proc Soc Exp Biol Med"},{"key":"2381_CR59","first-page":"S1","volume":"76","author":"Kidney Disease: Improving Global Outcomes","year":"2009","unstructured":"Kidney Disease: Improving Global Outcomes (2009) KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int 76:S1\u2013S130","journal-title":"Kidney Int"},{"key":"2381_CR60","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/ki.2010.352","volume":"79","author":"K Wesseling-Perry","year":"2011","unstructured":"Wesseling-Perry K, Pereira RC, Sahney S, Gales B, Wang HJ, Elashoff R, J\u00fcppner H, Salusky IB (2011) Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 79:112\u2013119","journal-title":"Kidney Int"},{"key":"2381_CR61","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0735-1097(01)01781-8","volume":"39","author":"P Raggi","year":"2002","unstructured":"Raggi P, Boulay A, Chasan-Taber S, Amin N, Dillon M, Burke SK, Chertow GM (2002) Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695\u2013701","journal-title":"J Am Coll Cardiol"},{"key":"2381_CR62","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1523-1755.2005.00517.x","volume":"68","author":"KJ Martin","year":"2005","unstructured":"Martin KJ, J\u00fcppner H, Sherrard DJ, Goodman WG, Kaplan MR, Nassar G, Campbell P, Curzi M, Charytan C, McCary LC, Guo MD, Turner SA, Bushinsky DA (2005) First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 68:1236\u20131243","journal-title":"Kidney Int"},{"key":"2381_CR63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000106792","volume":"107","author":"M Nakane","year":"2007","unstructured":"Nakane M, Ma J, Ruan X, Kroeger PE, Wu-Wong R (2007) Mechanistic analysis of VDR-mediated renin suppression. Nephron Physiol 107:35\u201344","journal-title":"Nephron Physiol"},{"key":"2381_CR64","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1210\/jc.2008-0326","volume":"94","author":"K Wesseling-Perry","year":"2009","unstructured":"Wesseling-Perry K, Pereira RC, Wang H, Elashoff RM, Sahney S, Gales B, J\u00fcppner H, Salusky IB (2009) Relationship between plasma fibroblast growth factor-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 94:511\u2013517","journal-title":"J Clin Endocrinol Metab"},{"key":"2381_CR65","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","volume":"9","author":"F Koiwa","year":"2005","unstructured":"Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T (2005) Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 9:336\u2013339","journal-title":"Ther Apher Dial"},{"key":"2381_CR66","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.bone.2009.08.008","volume":"45","author":"RC Pereira","year":"2009","unstructured":"Pereira RC, J\u00fcppner H, Azucena-Serrano CE, Yadin O, Salusky IB, Wesseling-Perry K (2009) Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 45:1161\u20131168","journal-title":"Bone"},{"key":"2381_CR67","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","volume":"119","author":"OM Gutierrez","year":"2009","unstructured":"Gutierrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545\u20132552","journal-title":"Circulation"},{"key":"2381_CR68","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00467-011-1822-0","volume":"26","author":"PR Srivaths","year":"2011","unstructured":"Srivaths PR, Goldstein SL, Silverstein DM, Krishnamurthy R, Brewer ED (2011) Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 26:945\u2013951","journal-title":"Pediatr Nephrol"},{"key":"2381_CR69","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ki.2010.316","volume":"78","author":"D Borzych","year":"2010","unstructured":"Borzych D, Rees L, Ha IS, Chua A, Valles PG, Lipka M, Zambrano P, Ahlenstiel T, Bakkaloglu SA, Spizzirri AP, Lopez L, Ozaltin F, Printza N, Hari P, Klaus G, Bak M, Vogel A, Ariceta G, Yap HK, Warady BA, Schaefer F (2010) The bone and mineral disorder of children undergoing chronic peritoneal dialysis. Kidney Int 78:1295\u20131304","journal-title":"Kidney Int"},{"key":"2381_CR70","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1053\/j.ajkd.2008.01.017","volume":"51","author":"D Joly","year":"2008","unstructured":"Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, Massart C, Moe SM, Monge M, Souberbielle JC (2008) Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 51:987\u2013995","journal-title":"Am J Kidney Dis"},{"key":"2381_CR71","doi-asserted-by":"crossref","first-page":"146","DOI":"10.2215\/CJN.05940611","volume":"7","author":"K Wesseling-Perry","year":"2012","unstructured":"Wesseling-Perry K, Pereira RC, Tseng CH, Elashoff R, Zaritsky JJ, Yadin O, Sahney S, Gales B, J\u00fcppner H, Salusky IB (2012) Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 7:146\u2013152","journal-title":"Clin J Am Soc Nephrol"},{"key":"2381_CR72","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/ki.1994.380","volume":"46","author":"WG Goodman","year":"1994","unstructured":"Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160\u20131166","journal-title":"Kidney Int"},{"key":"2381_CR73","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1046\/j.1523-1755.1998.00724.x","volume":"53","author":"BD Kuizon","year":"1998","unstructured":"Kuizon BD, Goodman WG, J\u00fcppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205\u2013211","journal-title":"Kidney Int"},{"key":"2381_CR74","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000057384","volume":"24","author":"BD Kuizon","year":"1998","unstructured":"Kuizon BD, Salusky IB (1998) Intermittent calcitriol therapy and growth in children with chronic renal failure. Miner Electrolyte Metab 24:290\u2013295","journal-title":"Miner Electrolyte Metab"},{"key":"2381_CR75","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1097\/01.ASN.0000129337.50739.48","volume":"15","author":"GM London","year":"2004","unstructured":"London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC (2004) Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 15:1943\u20131951","journal-title":"J Am Soc Nephrol"},{"key":"2381_CR76","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.2215\/CJN.01330210","volume":"5","author":"SA Bakkaloglu","year":"2010","unstructured":"Bakkaloglu SA, Wesseling-Perry K, Pereira RC, Gales B, Wang HJ, Elashoff RM, Salusky IB (2010) Value of the new bone classification system in pediatric renal osteodystrophy. Clin J Am Soc Nephrol 5:1860\u20131866","journal-title":"Clin J Am Soc Nephrol"},{"key":"2381_CR77","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1172\/JCI119851","volume":"100","author":"M Wada","year":"1997","unstructured":"Wada M, Furuya Y, Sakiyama J, Kobayashi N, Miyata S, Ishii H, Nagano N (1997) The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 100:2977\u20132983","journal-title":"J Clin Invest"},{"issue":"Suppl 3","key":"2381_CR78","first-page":"iii13","volume":"18","author":"M Wada","year":"2003","unstructured":"Wada M, Nagano N (2003) Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transplant 18[Suppl 3]:iii13\u2013iii17","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR79","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1093\/ndt\/gfn143","volume":"23","author":"K Nakagawa","year":"2008","unstructured":"Nakagawa K, Perez EC, Oh J, Santos F, Geldyyev A, Gross ML, Schaefer F, Schmitt CP (2008) Cinacalcet does not affect longitudinal growth but increases body weight gain in experimental uraemia. Nephrol Dial Transplant 23:2761\u20132767","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR80","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2215\/CJN.03630509","volume":"5","author":"JB Wetmore","year":"2010","unstructured":"Wetmore JB, Liu S, Krebill R, Menard R, Quarles LD (2010) Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clin J Am Soc Nephrol 5:110\u2013116","journal-title":"Clin J Am Soc Nephrol"},{"key":"2381_CR81","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","volume":"26","author":"P Raggi","year":"2011","unstructured":"Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J (2011) The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 26:1327\u20131339","journal-title":"Nephrol Dial Transplant"},{"key":"2381_CR82","doi-asserted-by":"crossref","unstructured":"The EVOLVE Trial Investigators (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367:2482\u20132494","DOI":"10.1056\/NEJMoa1205624"},{"key":"2381_CR83","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1681\/ASN.2009050531","volume":"21","author":"L Nguyen-Yamamoto","year":"2010","unstructured":"Nguyen-Yamamoto L, Bolivar I, Strugnell SA, Goltzman D (2010) Comparison of active vitamin D compounds and a calcimimetic in mineral homeostasis. J Am Soc Nephrol 21:1713\u20131723","journal-title":"J Am Soc Nephrol"},{"key":"2381_CR84","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5414\/CNP69269","volume":"69","author":"HH Malluche","year":"2008","unstructured":"Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, Coyne DW, Kaplan MR, Baker N, McCary LC, Turner SA, Goodman WG (2008) An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol 69:269\u2013278","journal-title":"Clin Nephrol"},{"key":"2381_CR85","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s00467-009-1294-7","volume":"25","author":"C Platt","year":"2010","unstructured":"Platt C, Inward C, McGraw M, Dudley J, Tizard J, Burren C, Saleem MA (2010) Middle-term use of Cinacalcet in paediatric dialysis patients. Pediatr Nephrol 25:143\u2013148","journal-title":"Pediatr Nephrol"},{"key":"2381_CR86","doi-asserted-by":"crossref","unstructured":"Padhi D, Langman CB, Fathallah-Shaykh S, Warady BA, Salusky IB, Lee E, Wang C, Posvar E (2012) An open-label study to evaluate a single-dose of cinacalcet in pediatric dialysis subjects. Pediatr Nephrol 17:1953\u20131959","DOI":"10.1007\/s00467-012-2186-9"},{"key":"2381_CR87","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/ndt\/gfp211","volume":"24","author":"J Bacchetta","year":"2009","unstructured":"Bacchetta J, Plotton I, Ranchin B, Vial T, Nicolino M, Morel Y, Cochat P (2009) Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism. Nephrol Dial Transplant 24:2595\u20132598","journal-title":"Nephrol Dial Transplant"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-012-2381-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-012-2381-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-012-2381-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,29]],"date-time":"2019-05-29T01:03:56Z","timestamp":1559091836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-012-2381-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,5]]},"references-count":87,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["2381"],"URL":"https:\/\/doi.org\/10.1007\/s00467-012-2381-8","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,5]]}}}